BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
35.11
-1.29 (-3.54%)
At close: Mar 28, 2025, 4:00 PM
34.91
-0.20 (-0.57%)
After-hours: Mar 28, 2025, 7:16 PM EDT

Company Description

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3.

The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases.

The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc.
BridgeBio Pharma logo
Country United States
Founded 2015
IPO Date Jun 27, 2019
Industry Biotechnology
Sector Healthcare
Employees 730
CEO Neil Kumar

Contact Details

Address:
3160 Porter Drive, Suite 250
Palo Alto, California 94304
United States
Phone 650 391 9740
Website bridgebio.com

Stock Details

Ticker Symbol BBIO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001743881
CUSIP Number 10806X102
ISIN Number US10806X1028
SIC Code 2834

Key Executives

Name Position
Dr. Eric Michael David J.D., M.D., Ph.D. Chief Executive Officer of Gene Therapy
Dr. Neil Kumar Ph.D. Co-Founder, Chief Executive Officer and Director
Dr. Charles J. Homcy M.D. Co-Founder, Chairman of Pharmaceuticals and Independent Lead Director
Dr. Frank P. McCormick Ph.D. Co-Founder, Chairman of Oncology and Director
Dr. Richard H. Scheller Ph.D. Chairman of Research and Development
Dr. Thomas Trimarchi Ph.D. Chief Financial Officer and President
Maricel M. Apuli Chief Accounting Officer
Dr. Uma Sinha Ph.D. Chief Scientific Officer
Eli M. Wallace Ph.D. Chief Scientific Officer of Oncology
Matthew Outten CPC, MBA Chief Commercial Officer

Latest SEC Filings

Date Type Title
Mar 17, 2025 8-K Current Report
Mar 12, 2025 SCHEDULE 13D/A Filing
Mar 7, 2025 SCHEDULE 13D/A Filing
Mar 6, 2025 144 Filing
Mar 5, 2025 144 Filing
Feb 28, 2025 8-K Current Report
Feb 25, 2025 144 Filing
Feb 25, 2025 144 Filing
Feb 20, 2025 10-K Annual Report
Feb 20, 2025 8-K Current Report